Lexicon Pharmaceuticals Inc (NAS:LXRX) Stock News, Headlines & Updates
Lexicon Pharmaceuticals Inc Stock News from GuruFocus
- 1
Aug 21, 2024
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
Marketwired • 7:00am
Aug 13, 2024
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Marketwired • 8:00am
Aug 01, 2024
Lexicon Pharmaceuticals (LXRX) Q2 2024 Earnings: EPS of -$0.17 Beats Estimates, Revenue of $1.6M Misses Expectations
GuruFocus Research • 4:09pm
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Marketwired • 3:00pm
Jul 25, 2024
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
Marketwired • 7:00am
Jul 16, 2024
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Marketwired • 7:00am
Jul 15, 2024
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
Marketwired • 7:00am
Jul 08, 2024
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Marketwired • 9:00am
Jun 21, 2024
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Marketwired • 7:00am
Jun 19, 2024
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Marketwired • 7:00am
Jun 18, 2024
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
Marketwired • 7:00am
Jun 14, 2024
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Marketwired • 7:00am
May 29, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news